BIOPHARMA’S Pharmacokinetic TEAM

BioPharma’s team of Pharmacokinetic Scientists are experts in their field, having generated thousands of study designs to support drug submissions to multiple regulatory markets across the globe. The team is also responsible for developing innovative design solutions for all drug programs from generic equivalents to new drug candidates.

Dr. Janice Faulknor MD, CCFP, Medical Director and Principal Investigator – 15 years of research experience in HAP and Abuse Deterrent Assessment.

Dr. Isabella Szeto MD, CCFP, FCFP, CPI, PrincipalInvestigator – 13 years of clinical research experience with 200+ studies.

Dr. John Oldenhof, MSc, PhD, VP of Clinical Pharmacology – 18 years of experience having overseen 250+ early phase and HAP and Abuse

Deterrent Assessment studies

Shein Nanji, Manager of Subject Recruitment with over 10 years of experience building a robust database of recreational drug user.

All study designs and clinical development plans at BioPharma are supported by our panel of expert Medical Physicians that ensure foremost that the safety and well-being of our study volunteers is priority. Whether the strategy is to dose a generic drug equivalent in healthy volunteers versus a patient panel or proceed with a new drug candidate, our Physician team’s primary objective is to maintain the health and welfare of our subjects with ethical and safety considerations driving their decisions. By understanding the drug product’s pharmacokinetics, pharmacodynamics, mechanism of action and potential serious or adverse events, our Physicians provide safe, reliable, data driven solutions to clinical development programs.

View our other Services